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Abstract Siah-1, the human homologue of Drosophila seven in
absentia, is related to apoptosis and tumor suppression.
Although it was reported that the expression of Siah-1 is
induced by p53 and p21/WAF1, little is known about the
transcriptional regulation of the Siah-1 gene. To investigate the
transcriptional regulation, we isolated and sequenced the
genomic fragment of the Siah-1 promoter region. The Siah-1
promoter has no typical TATA box or CCAAT box. Transient
transfection assays using reporter plasmids in which the
promoter region of the Siah-1 gene was deleted or mutated
showed that one Sp1 site was responsible for the basal promoter
activity. In Northern blotting analysis, the expression of the
Siah-1 gene was upregulated by p53, but activation of the
reporter plasmid by the p53 co-transfection assay was not
shown, suggesting that a p53 responsive element does not exist
in the promoter region we examined in this study but might be
present in another region. ß 2002 Published by Elsevier Sci-
ence B.V. on behalf of the Federation of European Biochemical
Societies.
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1. Introduction
Siah-1 is a human homologue of the Drosophila seven in
absentia (SINA), which plays an important role during eye
development [1]. Neuronal di¡erentiation of the R7 photore-
ceptor cell in the Drosophila eye requires SINA, the transcrip-
tion repressor Tramtrack [2] and PHYL, which is induced by
the RAS pathway [3]. SINA binds UBCD1 (E2) via the
N-terminal RING ¢nger domain and interacts with PHYL,
and the complex induces degradation of Tramtrack via the
ubiquitin proteasome pathway [4].
Siah family proteins, such as Siah-1 and Siah-2 in human,
are widely conserved in Drosophila and vertebrates [5]. The
Siah-1 gene product also has a RING ¢nger domain that
displays 76% amino acid identity with the SINA protein [6].
The N-terminal RING ¢nger domain of the Siah-1 protein
also interacts with ubiquitin conjugating enzyme (E2) [7]
and promotes degradation of various target proteins via the
ubiquitin-proteasome pathway. So far, it has been reported
that mammalian Siah proteins promote the proteolysis of
DCC, N-CoR and c-Myb via the ubiquitin-proteasome path-
way [8^11].
On the other hand, the tumor suppressor gene p53 is most
frequently mutated in human malignant tumors [12]. In re-
sponse to DNA damage, p53 induces apoptosis or cell cycle
arrest. p53 stimulates the degradation of c-Myb, which is
mediated by induction of Siah-1 in certain types of cells
[11]. It was recently revealed that Siah-1 induced by p53 in-
teracts with SIP, SKip and Ebi to promote degradation of L-
catenin by the ubiquitin-proteasome pathway [13,14]. More-
over, the expression of Siah-1 was induced in KS cells having
lost the malignant phenotype. The KS cells were derived from
K562 cells, and the KS cells interestingly reexpressed p53
[15,16], raising the possibility that p53 might induce Siah-1
to suppress the malignant phenotype. Actually, the overex-
pression of p53 was shown to increase human Siah-1
mRNA in 293 cells [17].
As mentioned above, the Siah-1 gene may be an important
molecule for tumor suppression and apoptosis. However, the
transcriptional regulation of the Siah-1 gene is unclear. To
investigate the expression machinery of the Siah-1 gene, we
cloned the Siah-1 promoter, and we clari¢ed the basic struc-
ture of the human Siah-1 gene.
2. Materials and methods
2.1. Genome screening of Siah-1 promoter region
A VPS library from human peripheral blood leukocytes (Mo Bi Tec,
Go«ttingen, Germany) was screened by two oligonucleotide probes
which contained the Siah-1 cDNA exon 1 sequence. The sequences
of the probes are as follows; Siah-b [5P-GACGGAGCGCGT-
TGGTGCCAGGACCGGGGT-3P] (sense) and Siah-a [5P-TTCC-
CGGCGCCGAGACCGACGGGACACCCT-3P] (antisense). Ap-
proximately 3.8U106 plaques were lifted on Hybond N nylon ¢lters
(Amersham). The ¢lters were hybridized with end-labeled oligonucleo-
tide probes at 50‡C overnight and washed at room temperature. Iso-
lated clones were con¢rmed by Southern blot and sequence analysis
using oligonucleotides Siah-a and Siah-b.
2.2. Plasmid construction and mutagenesis
The Siah-1 promoter region with 3528 bp was subcloned into the
luciferase reporter plasmid, pGVB2 (Toyo Ink, Tokyo, Japan). Dele-
tion mutants were generated using the Blunt end kit (Takara, Tokyo,
Japan) at speci¢c restriction enzyme sites. Plasmids with point muta-
tions at Sp1 sites were generated by the Quick Change Site-Directed
Mutagenesis Kit (Stratagene).
2.3. Cell culture
Human embryonic kidney 293 cells, human osteosarcoma Saos-2
cells and breast cancer MCF7 cells were cultured in Dulbecco’s modi-
¢ed Eagle’s medium with 10% fetal bovine serum and incubated at
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37‡C in a humidi¢ed atmosphere of 5% CO2. Human erythroleukemia
K562 cells were cultured in RPMI with 10% fetal bovine serum.
2.4. Luciferase assay
Breast cancer MCF7 cells were transfected with 2 Wg of reporter
plasmid by the DEAE-dextran method and the cells were harvested 48
h after transfection. In p53 co-transfection assays, 0.5 Wg of reporter
plasmid and 0, 25 or 250 ng of p53 expression plasmid were trans-
fected into Saos-2 cells with Lipofectamine Plus reagent (Gibco BRL).
After 24 h, the cells were harvested. Luciferase activity was analyzed
using the PicaGene luminescence kit (Toyo Ink). Relative luciferase
activity was standardized by the protein concentration of each cell
lysate. All transfection assays were carried out in triplicate. Each
experiment was repeated at least three times. Data are shown as
means þ S.D. (n = 3). Data were analyzed using the Student’s t-test
and di¡erences were considered signi¢cant from controls when
P6 0.05.
2.5. Northern blotting
Human osteosarcoma Saos-2 cells were plated in 10 cm dishes 24 h
before transfection of 10 Wg of p53 expression plasmids by Lipofect-
amine Plus reagent. The 293 cells and K562 cells were treated with the
same procedure. Total RNA was extracted at each indicated time.
Total RNA (10 Wg) was run on a denaturing agarose gel and trans-
ferred to a Nylon membrane (PALL, Biodyne). After hybridization
with 32P-labeled cDNA probes, signals were detected by autoradiog-
raphy and with a Bioimaging analyzer (BAS2000; Fuji Film, Tokyo,
Japan).
3. Results
3.1. Cloning and characterization of 5P-£anking region of the
human Siah-1 gene
We obtained a 16.5 kb Siah-1 genomic fragment containing
the 5P-£anking region of exon 1 by screening the human ge-
nomic library from peripheral blood leukocytes. We se-
quenced a 3528 bp fragment upstream of exon 1. As partially
shown in Fig. 1, the upstream region of exon 1 from 3544 to
+183 has an especially high GC content (76.1%). By computer
analysis, we could ¢nd the elements that are related to di¡er-
entiation and cell cycle regulation factors, such as GATA-1,
CdxA, nuclear factor-UB, v-Myb, E2F and so on (Fig. 1). The
5P-£anking region of the Siah-1 gene has neither typical
TATA box nor CCAAT box, but there are three copies of
Sp1 sites. We also found two incomplete p53 consensus se-
quences which have one point mutation in two copies of a
10 bp motif 5P-PuPuPuC(A/T)(A/T)GpyPyPy-3P [18] at posi-
tions from 33236 to 33207 and 3618 to 3596. We could not
identify the transcriptional start site of the Siah-1 gene using a
primer extension assay, Cap Site cDNA dT (Nippon Gene) or
RNase protection assay presumably due to the GC-rich se-
quence of exon 1.
3.2. Promoter activity of the Siah-1 gene
The 2515 bp DNA fragment of the 5P-£anking region of
exon 1 was subcloned into the pGVB2 luciferase reporter
plasmid and a transient transfection assay was performed
(Fig. 2). The pSiah-KpnI/32332 construct demonstrated
enough luciferase activity compared with that using negative
vector pGVB2. This result indicates that the 2515 bp DNA
fragment (pSiah-KpnI) has authentic promoter activity. Next,
we constructed several deletion mutants and measured each of
their promoter activities. We observed the maximum pro-
moter activity when the deletion mutant pSiah-NheI/3297
was transfected into MCF7 cells. The luciferase activity of
pSiah-NheI was higher than those of the longer constructs,
pSiah-MluI/3650 or pSiah-BalI/3923, which suggests the ex-
istence of a repression site between 3923 and 3298. The lu-
ciferase activity signi¢cantly decreased between pSiah-NheI
Fig. 1. Sequence of the Siah-1 promoter. The potential binding sites
of transcription factors and exon 1 are boxed. Arrows in the DNA
sequence indicate the 5P-terminus of deletion mutants. In this report,
we assume that the most upstream exon 1 of the Siah-1 cDNA pre-
viously reported (GenBank accession number U76247) was at posi-
tion +1.
Fig. 2. Deletion analysis of the Siah-1 promoter in MCF7. Each
plasmid (2 Wg) was transiently transfected into MCF7 cells by the
DEAE-dextran method. Luciferase activity was analyzed 48 h after
transfection. Relative luciferase activity was standardized by protein
concentration. Data are shown as means þ S.D. (n = 3). **P6 0.005.
Fig. 3. Mutation analysis to identify the basal promoter activity of
the Siah-1 gene in MCF7. Each construct is shown schematically on
the left. pSiah-mSp1, pSiah-mSp2 and mSp12 mutants contained the
following sequence: pSiah-mSp1 (3114 to 3109: cccgcc caagtt),
pSiah-mSp2 (331 to 326: ggcggg aacttg) and pSiah-mSp12 plasmid
has two mutations of the Sp1 sites. Data are shown as means þ S.D.
(n = 3). *P6 0.05.
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and pSiah-XhoI/+51. We considered that there might be im-
portant elements for the basal promoter activity between
3297 and +50.
3.3. Two Sp1 sites are involved in transcriptional activation of
the Siah-1 promoter
We found two Sp1 sites between 3297 and +50 (Fig. 1).
Therefore, we hypothesized that these two Sp1 sites might
contribute to the basal promoter activity of Siah-1. To deter-
mine whether these Sp1 sites are responsible for basal pro-
moter activity, we constructed reporter plasmids containing a
deletion or point mutation in two Sp1 sites (Fig. 3). A signi¢-
cant reduction was observed using pSiah-mSp1, pSiah-Sp1
and pSiah-mSp12. These constructs have deletions or point
mutations in the 5P-Sp1 site (3114 to 3109). These results
indicated that the 5P-Sp1 site was important for basal pro-
moter activity, and that the 3P-Sp1 site (331 to 326) does
not contribute to the basal promoter activity.
3.4. Transcriptional activation of Siah-1 by the
tumor-suppressor gene p53
Since the Siah-1 promoter region has two incomplete p53
consensus sequences from 33236 to 33207 and from 3618 to
3596, we examined whether its expression is induced by wild-
type p53 via the promoter region. First, we carried out North-
ern blotting to examine the endogenous Siah-1 induction by
p53 using three cell lines, the osteosarcoma cell line Saos-2
(p53 null), the human kidney epithelial cell line 293 (p53 is
inactivated by infection of adenovirus) and the human eryth-
roleukemic cell line K562 (p53 mutation) (Fig. 4). The
pCMVneoBam vector was used as a negative control for the
p53 expression plasmid. We detected two transcripts that
might be alternative splicing products, which have been pre-
viously reported [15]. The induction of Siah-1 mRNA was
increased in a time-dependent manner by wild-type p53 trans-
fection but not by a control vector in each cell line. The
expression of p21/WAF1 increased simultaneously with
Siah-1 expression (Fig. 4).
3.5. The Siah-1 promoter activity is downregulated by p53
We constructed a Siah-1 reporter plasmid containing two
incomplete p53 consensus sequences, pSiah-PF (Fig. 5), and
performed a transient transfection assay with pSiah-PF and
an increasing amount of p53 expression plasmid using Saos-2
cells (Fig. 5). Unexpectedly, the luciferase activity of pSiah-PF
was decreased by p53 in a dose-dependent manner. On the
other hand, the luciferase activity of the p21/WAF1 reporter
plasmid, pWWP-Luc, as a positive control was increased by
p53 in a dose-dependent manner.
4. Discussion
4.1. The characterization of the Siah-1 promoter
It has been reported that the Siah-1 gene is related to ap-
optosis and cell growth inhibition and is induced by the p53
tumor suppressor gene and p21/WAF1 [19,20]. However, little
was known about the machinery of Siah-1 expression. There-
fore, we clari¢ed the basic structure and activity of the Siah-1
promoter. At ¢rst, we cloned and sequenced the Siah-1 ge-
nomic fragment. We searched for putative transcription factor
binding sites in the 5P-£anking region of the Siah-1 gene. We
found elements related to di¡erentiation and cell cycle regu-
lation factors. Siah-1 may mediate signals of these factors and
induce di¡erentiation and cell cycle regulation. Further inves-
tigation will be required to clarify the mechanisms of expres-
sion and physiological function of the Siah-1 gene.
4.2. Sp1 site is important for promoter activity of Siah-1
We found two Sp1 sites spanning from 3114 to 3109 and
from 331 to 326 (Fig. 1). The 5P-Sp1 site (3114 to 3109)
was shown to be essential for the basal promoter activity (Fig.
3). There was neither a TATA box nor a CCAAT box in the
proximal promoter region of the Siah-1 gene. TATA-less pro-
moters such as housekeeping gene promoter are GC-rich and
Fig. 4. Induction of Siah-1 mRNA by wild-type p53. Northern blot analysis was performed using total RNA from the indicated cell lines trans-
fected with a p53 expression plasmid or a negative control plasmid at the indicated time. The ¢lter was probed with Siah-1, and rehybridized
with p21/WAF1 cDNA.
Fig. 5. p53 does not transactivate the Siah-1 promoter in Saos-2
cells. The full-size Siah-1 reporter plasmid, pSiah-PF, containing the
promoter region spanning from 33345 to +183 and p21/WAF1 re-
porter plasmid, pWWP-Luc, as a positive control, were transiently
transfected with p53 expression plasmid, or a negative control plas-
mid. Luciferase activity was analyzed 24 h after transfection. Data
are shown as means þ S.D. (n = 3). *P6 0.05.
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contain a CCAAT box and a GC box, like the Sp1 site, as
core promoter elements instead of a TATA box [21,22]. The
Sp1 site (3114 to 3109) may act as a core promoter element
in the Siah-1 gene promoter.
4.3. Regulation of Siah-1 by p53
The overexpression of p53 in 293 cells induced Siah-1
mRNA undergoing cell growth inhibition [17]. We also con-
¢rmed that Siah-1 mRNA was increased by p53 overexpres-
sion in three di¡erent cell lines (Fig. 4). Next, we carried out a
p53 co-transfection reporter assay to investigate whether Siah-
1 expression might be regulated by p53 via the Siah-1 pro-
moter region, which we isolated in this study. However, our
reporter plasmid had no response to p53. These results indi-
cated that p53 might activate the Siah-1 gene through another
region. For example, other p53 target genes such as
GADD45, DR5, p53R2, IGF-BP3 and PUMA [23^28] have
p53 responsive elements in the intron region. The Siah-1 gene
may also have intronic p53 responsive elements. Otherwise,
Siah-1 induction by p53 may not be caused by transcription
but by mRNA stabilization.
4.4. Further possibilities for clinical application using the
Siah-1 promoter
In this study we con¢rmed that p53 induces Siah-1 gene
expression. p53 is inactivated in half of malignant tumor cells,
which cause disordered cell proliferation. Therefore, activa-
tion of Siah-1 should compensate for the loss of function of
p53. We proposed that methods for upregulating p53 target
genes would be useful for cancer therapy, and termed this
method ‘gene-regulating chemotherapy’ [29,30,31]. As a model
of this, histone deacetylase inhibitors, such as butyrate or
trichostatin A, stimulate the p21/WAF1 gene, a p53 target
gene, through the Sp1 sites of the promoter independent of
p53, resulting in cell cycle arrest [32,33]. Therefore, our ¢nd-
ings and methods in this study may be suitable for screening
the regulators of Siah-1 expression. The screening of these
regulators may be important in the development of novel
cancer therapy as well as understanding the physiological
function of Siah-1.
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